

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM690336

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
SEQUENCE:	2		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BAUSCH + LOMB IRELAND LIMITED		11/23/2021	Private Limited Company: IRELAND
RECEIVING PARTY DATA			
Name:	The Bank of New York Mellon, as Notes Collateral Agent		
Street Address:	101 Barclay Street, Floor 7E		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10286		
Entity Type:	Corporation: NEW YORK		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	90471068	IMMUNE DUO	
CORRESPONDENCE DATA			
Fax Number:			
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	8004945225		
Email:	ipteam@cogencyglobal.com		
Correspondent Name:	JAY DASILVA		
Address Line 1:	1025 CONNECTICUT AVE., NW, STE. 712		
Address Line 2:	COGENCY GLOBAL INC.		
Address Line 4:	WASHINGTON, D.C. 20036		
ATTORNEY DOCKET NUMBER:	1529686 TM D		
NAME OF SUBMITTER:	Ashley Kim		
SIGNATURE:	/Ashley Kim/		
DATE SIGNED:	11/24/2021		
Total Attachments: 9			
source=D - Trademark IPSA - Q3 2021 (BNY)#page2.tif			
source=D - Trademark IPSA - Q3 2021 (BNY)#page3.tif			

OP \$40.00 90471068

source=D - Trademark IPSA - Q3 2021 (BNY)#page4.tif
source=D - Trademark IPSA - Q3 2021 (BNY)#page5.tif
source=D - Trademark IPSA - Q3 2021 (BNY)#page6.tif
source=D - Trademark IPSA - Q3 2021 (BNY)#page7.tif
source=D - Trademark IPSA - Q3 2021 (BNY)#page8.tif
source=D - Trademark IPSA - Q3 2021 (BNY)#page9.tif
source=D - Trademark IPSA - Q3 2021 (BNY)#page10.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of November 23, 2021, (this “**Agreement**”), among the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) and The Bank of New York Mellon, as collateral agent for the Noteholder Secured Parties (in such capacity, together with its successors and permitted assigns, the “**Notes Collateral Agent**”).

Certain Grantors (the “**US Grantors**”) are party to the U.S. Pledge and Security Agreement dated as of October 17, 2017 (as amended or otherwise modified, the “**October Security Agreement**”), the U.S. Pledge and Security Agreement dated as of March 8, 2019 (as amended or otherwise modified, the “**March 2019 Security Agreement**”) and the U.S. Pledge and Security Agreement dated as of June 8, 2021 (as amended or otherwise modified, the “**June 2021 Security Agreement**”, and, together with the October 2017 Security Agreement and the March 2019 Security Agreement, the “**Security Agreements**”) between each of the US Grantors and the other grantors party thereto and the Notes Collateral Agent pursuant to which the US Grantors granted a security interest to the Notes Collateral Agent in the IP Collateral (as defined below) and are required to execute and deliver this Agreement. Consistent with the requirements set forth in Section 4.3 of the Security Agreements, the parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreements.

SECTION 2. **Grant of Security Interest.** As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, each Grantor, pursuant to the Security Agreements, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Notes Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of such Grantor and regardless of where located (the Trademark Collateral, Patent Collateral and Copyright Collateral, each as defined below, collectively, the “**IP Collateral**”):

- A. The “**Trademark Collateral**”, defined as set forth in paragraphs (1) through (4) directly below:
 - 1. all Trademarks, including those Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto;
 - 2. all goodwill associated with or symbolized by the Trademarks;
 - 3. the right to sue third parties for past, present and future infringements, dilutions or violations of any Trademark; and
 - 4. all proceeds of and rights associated with the foregoing;

- B. The “**Patent Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:
 - 1. all Patents, including those Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;
 - 2. the right to sue third parties for past, present and future infringements of any Patent; and
 - 3. all proceeds of and any right associated with the foregoing; and

C. The “**Copyright Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Copyrights, including those Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III;
2. the right to sue third parties for past, present and future infringements of any Copyright, and
3. all proceeds of and rights associated with the foregoing;

Notwithstanding anything to the contrary in (A) through (C) above, this Agreement shall not constitute a grant of a security interest in any Excluded Assets, including any “intent-to-use” Trademark applications prior to the filing and acceptance of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto.

SECTION 3. Security Agreement. The security interests granted to the Notes Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Notes Collateral Agent pursuant to the Security Agreements. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Notes Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreements, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreements, the terms of the Security Agreements shall govern.

SECTION 4. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

SECTION 5. Counterparts. This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]

BAUSCH HEALTH IRELAND LIMITED

By: 


Name: William N. Woodfield
Title: Director

BAUSCH+LOMB IRELAND LIMITED

By: 


Name: William N. Woodfield
Title: Director

SALIX PHARMACEUTICALS, INC.

By: 


Name: William N. Woodfield
Title: Vice President, Treasurer

BAUSCH & LOMB INCORPORATED

By: 


Name: William N. Woodfield
Title: Vice President, Treasurer

BAUSCH HEALTH US, LLC

By: 

Name: William N. Woodfield
Title: Senior Vice President, Treasurer

SOLTA MEDICAL, INC.

By: 

Name: William N. Woodfield
Title: Director

SOLTA MEDICAL IRELAND LIMITED

By:

Name: Jeremy Lipshy
Title: Director

[Signature Page to IPSA – BNY]


TRADEMARK
REEL: 007505 FRAME: 0386

SOLTA MEDICAL, INC.

By:

Name: William N. Woodfield
Title: Director

SOLTA MEDICAL IRELAND LIMITED



By:


Name: Jeremy Lipshy
Title: Director

[Signature Page to IPSA – BNY]

TRADEMARK
REEL: 007505 FRAME: 0387

Accepted and Agreed:

THE BANK OF NEW YORK MELLON,
as Notes Collateral Agent

By:  Digitally signed by
Lisa Sollitto
Date: 2021.11.23
13:49:45 -05'00'

Name: Lisa Sollitto
Title: Vice President

Schedule I - Trademark Collateral Schedule I - Trademark Collateral

Current Owner on TMO Records	Mark Name	Current Application Number	Current Registration Number
BAUSCH + LOMB IRELAND LIMITED	IMMUNE DUO	90471068	N/A

Schedule II – Patent Collateral

Appl. No.	Publ. No.	Patent No.	Title	Current PTO Owner
17/207222	2021-0205406-A1		FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	BAUSCH HEALTH IRELAND LIMITED
17/489939			PHARMACEUTICAL FORMULATIONS USEFUL FOR INHIBITING ACID SECRETION AND METHODS FOR MAKING AND USING THEM	SALIX PHARMACEUTICALS, INC.
63/243823			COMBINATIONS OF RIFAXIMIN AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER	BAUSCH HEALTH IRELAND LIMITED
63/239246			OPHTHALMIC DEVICES	BAUSCH + LOMB IRELAND LIMITED
17/462962			CONTACT LENS PACKAGING	BAUSCH + LOMB IRELAND LIMITED
63/239343			OPHTHALMIC DEVICES	BAUSCH + LOMB IRELAND LIMITED
63/239344			OPHTHALMIC DEVICES	BAUSCH + LOMB IRELAND LIMITED
17/398556			PACKAGING SOLUTIONS	BAUSCH + LOMB IRELAND LIMITED
17/397496			CONTACT LENS PACKAGING	BAUSCH & LOMB INCORPORATED
63/226614			METHODS FOR TREATING CONJUNCTIVITIS AND/OR COVID-19 USING BENZALKONIUM CHLORIDE	BAUSCH + LOMB IRELAND LIMITED
29/788730			LIGHT THERAPY DEVICE	SOLTA MEDICAL IRELAND LIMITED
17/366871	2021-0330681-A1		TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS	BAUSCH HEALTH US, LLC
17/365353			PHACOEMULSIFICATION HANDPIECE	BAUSCH + LOMB IRELAND LIMITED

None.

Schedule III - Copyright Collateral